Edition:
United States

Nightstar Therapeutics PLC (NITE.OQ)

NITE.OQ on NASDAQ Stock Exchange Global Select Market

15.48USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$15.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
7,643
52-wk High
$24.70
52-wk Low
$10.01

Latest Key Developments (Source: Significant Developments)

Nightstar Therapeutics Q1 Loss Per Share $0.52
Wednesday, 6 Jun 2018 06:35am EDT 

June 6 (Reuters) - Nightstar Therapeutics PLC ::NIGHTSTAR THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND ACCELERATION OF PRELIMINARY NSR-RPGR READOUT TO THIRD QUARTER 2018.Q1 LOSS PER SHARE $0.52.Q1 EARNINGS PER SHARE VIEW $-0.40 -- THOMSON REUTERS I/B/E/S.DOSE EXPANSION STUDY IN XIRIUS TRIAL EXPECTED TO BEGIN ENROLLMENT IN Q4 2018.AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $122.3 MILLION.ANTICIPATES PRELIMINARY DATA FROM EXPANSION STUDY IN MID 2019.  Full Article

Nightstar Therapeutics Reports 2017 Financial Results
Tuesday, 3 Apr 2018 05:15pm EDT 

April 4 (Reuters) - Nightstar Therapeutics PLC ::REPORTS 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.‍AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS TOTALED $129.4 MILLION, VERSUS $10.1 MILLION AT DEC 31, 2016​.  Full Article

Nightstar Therapeutics ADS open 23.2 pct above IPO price in debut
Thursday, 28 Sep 2017 10:12am EDT 

Sept 28 (Reuters) - :Nightstar Therapeutics Ltd ADS open at $17.25 in debut on the NASDAQ versus IPO price of $14/ADS.  Full Article

BRIEF-Nightstar Therapeutics Starts Star Phase 3 Registrational Trial For Nsr-Rep1 In Choroideremia

* NIGHTSTAR THERAPEUTICS ANNOUNCES INITIATION OF STAR PHASE 3 REGISTRATIONAL TRIAL FOR NSR-REP1 IN CHOROIDEREMIA